Abbrea Capital LLC Cuts Stock Holdings in Danaher Co. (NYSE:DHR)

Abbrea Capital LLC trimmed its position in shares of Danaher Co. (NYSE:DHR) by 1.7% in the 4th quarter, Holdings Channel.com reports. The firm owned 5,717 shares of the conglomerate’s stock after selling 100 shares during the period. Abbrea Capital LLC’s holdings in Danaher were worth $1,324,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. BKM Wealth Management LLC purchased a new stake in Danaher in the 4th quarter worth $27,000. Wetzel Investment Advisors Inc. acquired a new stake in Danaher during the 4th quarter worth $29,000. OFI Invest Asset Management acquired a new stake in Danaher during the 3rd quarter worth $30,000. Rakuten Securities Inc. acquired a new stake in Danaher during the 4th quarter worth $36,000. Finally, GHP Investment Advisors Inc. boosted its stake in Danaher by 540.0% during the 3rd quarter. GHP Investment Advisors Inc. now owns 160 shares of the conglomerate’s stock worth $40,000 after purchasing an additional 135 shares during the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

DHR has been the topic of several recent research reports. Royal Bank of Canada lifted their target price on shares of Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. Raymond James lifted their target price on shares of Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. Robert W. Baird boosted their price target on shares of Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research report on Wednesday. Barclays boosted their price target on shares of Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research report on Wednesday. Finally, HSBC raised shares of Danaher from a “hold” rating to a “buy” rating and boosted their price target for the company from $250.00 to $280.00 in a research report on Wednesday, April 17th. Six investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $270.00.

Danaher Trading Up 0.3 %

NYSE:DHR traded up $0.78 on Friday, reaching $246.58. 2,694,445 shares of the company’s stock were exchanged, compared to its average volume of 2,785,746. The company has a quick ratio of 1.37, a current ratio of 1.85 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $182.64 billion, a price-to-earnings ratio of 41.66, a price-to-earnings-growth ratio of 4.19 and a beta of 0.83. The business has a fifty day moving average of $248.94 and a 200-day moving average of $230.88. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $259.00.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. During the same period in the prior year, the company earned $2.36 earnings per share. The company’s revenue was down 2.6% compared to the same quarter last year. As a group, analysts expect that Danaher Co. will post 7.64 earnings per share for the current year.

Danaher Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Investors of record on Thursday, March 28th will be given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. This is a positive change from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date is Wednesday, March 27th. Danaher’s dividend payout ratio (DPR) is 18.31%.

Insider Activity at Danaher

In related news, SVP Georgeann Couchara sold 2,622 shares of Danaher stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total value of $636,280.74. Following the transaction, the senior vice president now directly owns 4,244 shares in the company, valued at approximately $1,029,891.48. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Danaher news, SVP Daniel Raskas sold 23,757 shares of the firm’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the sale, the senior vice president now owns 38,102 shares of the company’s stock, valued at $9,601,704. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Georgeann Couchara sold 2,622 shares of the firm’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total value of $636,280.74. Following the completion of the sale, the senior vice president now directly owns 4,244 shares of the company’s stock, valued at approximately $1,029,891.48. The disclosure for this sale can be found here. Insiders have sold a total of 84,132 shares of company stock worth $21,022,795 in the last three months. Insiders own 11.10% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.